SPDR Barclays 3-12 Month T-Bill ETF (BILS) Stock Price, Quote & News

Company Profile

In seeking to track the performance of the index, the fund employs a sampling strategy, which means that the fund is not required to purchase all of the securities represented in the index. The index is designed to measure the performance of public obligations of the U.S. Treasury that have a remaining maturity of greater than or equal to 3 months and less than 12 months.

BinaryLogic Dec. 9 at 2:20 AM

$SCNX [Again] Two (2) FDA approved drugs targeting unique/distinct markets totaling nearly $500M in domestic (US), annualized sales. Arbli was launched mid-August and already showed a $5M annualized run rate prior to scaling across national formularies. Exclusive IP protection thru 2041. Just a 15% penetration rate equates to $40-50M annualized revenue against a market cap of $25M. Separately-Rezenopy is scheduled to launch in Q1-2026 into a domestic market (narcan) measured in $BILS, though specific nasal spray retail approximates $150-200M. Another 15% penetration rate here implies $20-30M annualized revenue, accretive to Arbli. $40-60M revenue, multiple additional drugs under consideration in pipeline, experienced management launching novel pharma products, established production and marketing agreements. More than $8.0M in liquidity (equity placements) against debt that has largely been converted with $2.28 strike (appx). Multiplier upside (IMO) https://finance.yahoo.com/news/updated-lineup-announced-iaccess-alphas-140000061.html

2 · Reply

BinaryLogic Dec. 16 at 2:18 AM

$PTHRF $BILS

0 · Reply

BinaryLogic Dec. 14 at 11:23 AM

$ICCM So the Company has already shown ProSense cryoblation efficacy in breast tumor elimination, now similar strong results in treating benign/malignant kidney tumors. The Company is securing its technology across multiple (global) markets and verticals (breast, kidney, lung and liver) with a total addressable market measures in $BILS. ICCM has a $60MILS valuation. Watch the $1.4 resistance on the 1YR daily. If/where the SP breaks above that line, this could get very interesting (IMO). [Again] $0.55-0.60 was the place to start/build/add (below). https://finance.yahoo.com/news/icecures-prosense-cryoablation-safe-effective-133000097.html

0 · Reply

BinaryLogic Dec. 10 at 11:15 AM

$PTHRF Megrez-1 well has reached TD and production casing in-place, completed on-time and to budget. 1200ft section of HC 'discovery' (important) including light crude, 20% porosity, ongoing evaluation to better qualify the well, long-term testing likely. [Again] This Company and its assets should ultimately be measured in $BILS, currently at $0.3Bils market cap. I advocated for GBP 0.17 [$0.23] in August, re-inforced $0.30 just last week for those who were interested in a strong/speculative O&G investment with short/long term potential. 50-200% upside from this level [$0.30] near/intermediate term (IMO). https://polaris.brighterir.com/public/pantheon_resources/news/rns/story/rnj48kx

2 · Reply

BinaryLogic Sep. 30 at 12:45 PM

$JD Some workers in Finance/Strategy at $WMT will unfortunately be looking for new jobs, likely in the very near future. This was a colossal, unfortunate mistake measured in $BILS. The Company $WMT will obviously be fine - but what tremendous mistake, measured literally in days.

0 · Reply

ChartMill Nov. 19 at 6:04 AM

Pocket pivot signals in $MUI, $BILS, $RDY, $BKE and $DKS, while they also have the support from large players according to the effective volume indicator. https://www.chartmill.com/stock/stock-screener?sid=31&f=smlev20v_b_lev,smlev20v_r,p_pg10,pp_1,v1_50b200,cu_a_sm50v,der5_a_0.03,s_ppt,exch_us&v=3&timeframe=DAILY&type=CANDLES&o1=17&op1=10%252C2,16711680&i1=49&ia1=on&cl=F&months=0.05&o2=3&op2=50,255&width=720&o3=3&op3=10,65280&utm_source=large_effective_volume_+_pocket_pivot_today&utm_medium=stocktwits&utm_campaign=screen

0 · Reply